<?xml version="1.0" encoding="UTF-8"?>
<p>
 <xref rid="T1" ref-type="table">Table 1B</xref> summarizes clinical course and management. Two (6%) patients, ages 69 and 81, had a protracted–severe course, while the mean age of patients with an uncomplicated course was 42 years. Eight (22%) patients received treatment with entecavir or tenofovir, and only 2 of these met AASLD criteria for treatment due to a protracted–severe course.
</p>
